A service of arranging or bringing about contact between an investment manager and an issuer or potential issuer.
CARMEL, Ind., May 27, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, will...
Strengthens Balance Sheet and Provides Growth CapitalCARMEL, Ind., May 22, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and...
CARMEL, Ind., May 21, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today...
Company now exclusively focused on the growing fertility market following the April 2025 announcement to divest a majority stake in Naya TherapeuticsSARASOTA, Fla., May 20, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) ("INVO Fertility" or the...
CUPERTINO, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous...
- 446 participants completed the brilaroxazine long-term open-label extension (OLE) trial with 156 completing one-year and 301 completing six months of treatment - - Full data set from RECOVER OLE highlighting clinical response, safety, efficacy, adherence, and...
PONTE VEDRA, Fla. - Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing therapeutics for patients with cardiovascular disease, today announced manufacturing and supply chain milestones for its lead drug candidate, tecarfarin, a novel...
Expanded life science and industrial portfolio with six additional life science products in developmentAdvances toward commercialization of functional recombinant solutions for cell culture media, nucleic and industrial enzyme marketsUp to $4.5 million research grant...
Net income of $4.0 million, or $0.65 and $0.21 net income per share basic and diluted, respectivelyAdjusted EBITDA1 of $3.9 millionTotal net revenue of $18.5 million up 32% year-over-yearCompany to host conference call and webcast today, May 14, 2025, at 4:30 p.m....
PORTLAND, Maine, May 14, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and...
CUPERTINO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous...
Conference Call Scheduled for Thursday, May 15, 2025 at 9:00 AM ETPORTLAND, Maine, May 12, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets...
Conference call will be held today, Monday, May 12 at 9:00 am ETCARMEL, Ind., May 12, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and...
GARDNER, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (Nasdaq: POCI) (the "Company"), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, today announced that it has...
Leadership appointment strengthens strategic and development capabilities FDA Type D Meeting provides additional guidance for advancing the clinical development of tecarfarin Collaboration Agreement with Abbott (NYSE: ABT) validates the need for new anticoagulation...
DENVER, CO / ACCESS Newswire / May 7, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report its operational and financial results for its third quarter of fiscal 2025,...
WOBURN, MA / ACCESS Newswire / May 6, 2025 / Biofrontera Inc. (Nasdaq:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the commercialization of dermatological products, announces it will report financial results for the three months...
Financial results to be released before market open; Conference call to be conducted at 9:00 a.m. Eastern TimeCARMEL, Ind., May 05, 2025 -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing...
Announces Regular Quarterly Cash Dividend of $0.17 Per Share Reaffirms Full Year 2025 Revenue and Earnings Guidance Reports record revenue of $19.5 million for the first quarter of 2025, an increase of $1.9 million or 11%, compared to the same period in 2024.Reports...
JUPITER, Fla., May 01, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (Nasdaq: DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and...
SARASOTA, Fla., April 30, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) ("INVO Fertility" or the "Company"), a healthcare services fertility company focused on expanding access to advanced treatment through the establishment, acquisition and operation of...
CUPERTINO, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous...
WINTER SPRINGS, Fla., April 28, 2025 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by IRADIMED CORPORATION (NASDAQ: IRMD), please note that in the first paragraph the date of the earnings call should read "Monday, May 5, 2025" instead...
WINTER SPRINGS, Fla., April 28, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2025 first quarter financial results before the market opens on Friday, May 5, 2025. Iradimed management will host a...
SARASOTA, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: NAYA), formerly known as NAYA Biosciences, Inc., a healthcare services fertility company focused on expanding access to advanced treatment through the establishment, acquisition and...
CUPERTINO, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous...
Company to conduct 1x1 meetings on April 24, 2025 DENVER, CO / ACCESS Newswire / April 21, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that it will be...
Company to conduct 1x1 meetings on April 24, 2025GARDNER, Mass., April 21, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ: POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries,...
PONTE VEDRA, Fla. - Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company focused on the development of tecarfarin, a new Phase 3-ready oral vitamin K antagonist anticoagulant, today announced that Chairman and CEO Quang X. Pham will...
JUPITER, Fla., April 16, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (Nasdaq: DYAI), a biotechnology company that utilizes its microbial production platforms to develop commercial cell lines for the efficient...
CARMEL, Ind., April 15, 2025 -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced that it...
Public company to operate under new name and concentrate on building, acquiring and operating fertility clinics and the distribution of FDA-cleared INVOcell device Private company to operate as NAYA Therapeutics and focus on clinical development of bifunctional...
PORTLAND, Maine, April 08, 2025 -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy...
In this episode, we are featuring Aurora Spine Corporation (TSXV: ASG / OTCQB: ASAPF), a company focused on bringing new solutions to the spinal implant market through a series of proprietary, minimally invasive, and regenerative technologies. This interview is...
PORTLAND, Maine, April 07, 2025 -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy...
$3.1 million of new orders received during the current calendar year$6.6 million customer program backlog expected to be delivered over next 12 months$3.9 million of additional commitments expected to be received for calendar 2026 GARDNER, Mass., April 03, 2025 --...
Management Available for One-to-One Meetings PONTE VEDRA, Fla. - Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company focused on the development of tecarfarin, a new Phase 3-ready oral vitamin K antagonist anticoagulant, today announced...
PORTLAND, Maine, April 02, 2025 -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy...
GARDNER, Mass., March 27, 2025 -- Precision Optics Corporation, Inc. (NASDAQ: POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, today announced that it will participate in a webcasted fireside...
Strong revenue performance, including approximately $1.9 million milestone and license revenue recognized in 2024Up to $7.5 million in grants awarded from CEPI and Gates Foundation intended to accelerate the C1 platform development timeline to manufacture vaccines and...
JUPITER, Fla., March 20, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ: DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and...
GARDNER, Mass., March 20, 2025 -- Precision Optics Corporation, Inc. (NASDAQ: POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, is pleased to announce the appointment of Joseph P. "JJ"...
Conference call will be held today, Thursday, March 20 at 9:00 am ETCARMEL, Ind., March 20, 2025 -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating...
SARASOTA, Fla. and MIAMI, March 13, 2025 (GLOBE NEWSWIRE) -- NAYA Biosciences, Inc. ("NAYA") (NASDAQ: NAYA), a life science portfolio company dedicated to bringing breakthrough treatments to patients in oncology, autoimmune diseases, and women's health, and a leading...
Recent Collaboration Agreement with Abbott Global Enterprises Limited ("Abbott") in support of Phase 3 randomized, multicenter study, entitled TECH-LVAD Recent FDA Type D Meeting provides additional guidance for advancing clinical development of tecarfarin Leadership...
JUPITER, Fla., March 12, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (Nasdaq: DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and...
CARMEL, Ind., March 12, 2025 -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, will report summarized...
WINTER SPRINGS, Fla., March 10, 2025 -- IRADIMED CORPORATION (the "Company") (NASDAQ: IRMD) today announced that it will participate in the 37th Annual Roth Conference. Iradimed's CFO, Jack Glenn, and CCO, Jeff Chiprin, will host one-on-one meetings between company...
JUPITER, Fla., March 06, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (Nasdaq: DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and...
GARDNER, Mass., March 04, 2025 -- Precision Optics Corporation, Inc. (NASDAQ: POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, is pleased to announce the appointment of Buell Duncan to its...